Celtic Pours More Private Equity Into The Promise Of Antibody-Drug Conjugates
This article was originally published in Start Up
Celtic Therapeutics will put as much as $50 million into ADC Therapeutics to develop next-generation cancer drugs based on assets from Spirogen, another of its other portfolio companies.
You may also be interested in...
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
FDA approves the antibody-drug conjugate for late stage Hodgkins lymphoma and systemic anaplastic large cell lymphoma Aug. 19.
The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.